Table 3. Intake of n-3 LC-PUFAs and risk of AF.
| N-3 LC-PUFA, tertilesa |
STRATAb | |||
|---|---|---|---|---|
| Stratum 1 | Stratum 2 | Stratum 3 | ||
| (age 50–65 y) | (age 55–70 y) | (age 60–75 y) | ||
| MODEL 1c | 1 | REF | REF | REF |
| 2 | 0.07 (-0.5, 0.7) | -0.26 (-1.0, 0.5) | -0.90 (-1.8, 0.1) | |
| 3 | 0.45 (-0.2, 1.1) | 0.33 (-0.5, 1.2) | -0.25 (-1.2, 0.8) | |
| MODEL 2d | 1 | REF | REF | REF |
| 2 | 0.18 (-0.4, 0.8) | -0.17 (-1.0, 0.6) | -0.66 (-1.6, 0.3) | |
| 3 | 0.67 (-0.04, 1.4) | 0.53 (-0.4, 1.4) | 0.26 (-0.8, 1.3) | |
Risk of AF is given by age-specific cumulative risk differences (RD in %) with 95% CI in parentheses
aTertiles of intake of n-3 LC-PUFAs (EPA, DPA and DHA)
- Category boundaries for the tertiles, T1-T3 (g/d):
- Stratum 1, T1(0–0.46) T2(0.46–0.75) T3(0.75–5.28)
- Stratum 2, T1(0–0.49) T2(0.49–0.79) T3(0.79–6.35)
- Stratum 3, T1(0–0.52) T2(0.52–0.86) T3(0.86–7.22)
bStratum 1, 2 and 3 were defined by baseline age tertiles
cModel 1 included baseline age, sex, BMI, waist circumference, alcohol intake, smoking, fish oil supplements, angina pectoris, diabetes, and hypertension
dModel 2 included variables in model 1 and intake of α-LA